# Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

> **NCT06603558** · — · RECRUITING · sponsor: **AbbVie** · enrollment: 3000 (estimated)

## Conditions studied

- Chronic Migraine
- Episodic Migraine
- Migraine

## Interventions

- **DRUG:** Atogepant

## Key facts

- **NCT ID:** NCT06603558
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-24
- **Primary completion:** 2029-05
- **Final completion:** 2029-05
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603558, "Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06603558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*